Sponsored by Novartis Medical Affairs | December 30, 2025

LIMITATIONS: The analyses for this poster were exploratory, and no statistical testing was applied. 

DISCLAIMER: The content provided herein is for your background and educational purposes only and may not be altered or further disseminated in any fashion. Please refer to full Prescribing Information.

The SUNSHINE and SUNRISE phase 3 trials demonstrated sustained treatment efficacy and a favorable safety profile of secukinumab in adults with moderate to severe hidradenitis suppurativa (HS). This post hoc analysis of the SUNSHINE/SUNRISE core trials aimed to compare differences in clinical responses to secukinumab treatment based on disease duration and/or Hurley staging.

In SUNSHINE and SUNRISE, patients with moderate to severe HS were randomized 1:1:1 to receive subcutaneous secukinumab 300 mg every 2 (SECQ2W) or 4 weeks (SECQ4W), or placebo for 16 weeks. At week 16, patients receiving placebo were switched to SECQ2W or SECQ4W, while those receiving SECQ2W or SECQ4W remained on the same treatment through week 52. 

In this analysis, the proportion of patients achieving HS Clinical Response (HiSCR)50, HiSCR75, HiSCR90, and HiSCR100 through week 52 was assessed according to disease duration, Hurley staging, and by a combination of these in the following subgroups: early/moderate, early/severe, late/moderate, and late/severe. Data presented are observed, pooled data from both trials, irrespective of secukinumab dosing regimen, and include patients who switched from placebo at week 18.

Overall, 1084 patients who were treated with secukinumab were included in this analysis. Through week 52, disease duration and/or Hurley staging did not influence HiSCR50 responses but positively influenced response to secukinumab for higher thresholds of clinical response at week 52:

• An increased proportion of patients with <5 years disease duration reported achieving HiSCR75, HiSCR90, and HiSCR100 vs those with ≥5 years disease duration
• Higher proportions of patients with Hurley stage I and II disease at baseline reported HiSCR75, HiSCR90, and HiSCR100 (43.4%, 25.6%, and 20.5%, respectively) vs patients with Hurley stage III disease at baseline (35.5%, 20.1%, and 11.1%, respectively)

In the combined subgroups, the proportions of patients reporting HiSCR100 at week 52 were: 24.9% for early/ moderate, 11.6% for early/severe, 14.7% for late/moderate, and 10.6% for late/severe patients.  

Secukinumab Indications and Important Safety Considerations

Indications

Secukinumab is a human interleukin-17A antagonist indicated for the treatment of:

• Moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy
• Active psoriatic arthritis (PsA) in patients 2 years of age and older
• Adults with active ankylosing spondylitis (AS)
• Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation
• Active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older
• Adults with moderate to severe hidradenitis suppurativa (HS)

Important Safety Considerations

Contraindications: Serious hypersensitivity to secukinumab or any excipients in secukinumab

Warnings and Precautions: 

Infections: Serious infections have occurred. Exercise caution when considering the use of secukinumab in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue secukinumab until the infection resolves.

Hypersensitivity Reactions: If an anaphylactic reaction or other serious allergic reaction occurs, discontinue secukinumab immediately and initiate appropriate therapy.

Tuberculosis (TB): Prior to initiating treatment with secukinumab, evaluate for TB.

Inflammatory Bowel Disease (IBD): Cases of IBD were observed in clinical trials. Exercise caution when prescribing secukinumab to patients with IBD.

Eczematous Eruptions: Cases of severe eczematous eruptions have occurred in patients receiving secukinumab.

Immunizations: Avoid use of live vaccines in patients treated with secukinumab.

Adverse Reactions: Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection. 

This poster was previously presented at the 10th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA 2025), Nashville, TN, USA, October 31-November 2, 2025. 

Novartis has paid DermSquared to host this content. Novartis is solely responsible for all the written content within this presentation.

© 2025 Novartis. All rights reserved.

12/25 FA-11569624